Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Lymphoid 2Dermatologic 1

Conditions

Mycosis Fungoides 2Neoplasms 1Lymphoma, T-Cell, Cutaneous 1

Interventions

Rituximab 376Cyclophosphamide 179Bendamustine Hydrochloride 109obinutuzumab 100Vincristine 94fludarabine 92ibrutinib 89Prednisone 89Doxorubicin 89venetoclax 86Lenalidomide 82Gemcitabine 65acalabrutinib 48Brentuximab Vedotin 44pembrolizumab 43zanubrutinib 41Dexamethasone 41idelalisib 37ofatumumab 32Oxaliplatin 30Chlorambucil 29polatuzumab vedotin 25blinatumomab 25tocilizumab 24Azacitidine 24tositumomab I-131 22Prednisolone 22tisagenlecleucel 21glofitamab 21Nivolumab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Amines × Lymphoid × Clear all
NCT06149247 2025-08-20

HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL

Soligenix

Phase 2 Completed
10 enrolled 7 charts
Lymphoid

Mycosis Fungoides

NCT02296164 2020-03-04

PROVe

Helsinn Therapeutics (U.S.), Inc

Completed
300 enrolled 7 charts
DermatologicLymphoid

Mycosis Fungoides, Neoplasms, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡